AR096444A1 - QUIMERAS DE LUMAZINA SINTASA DE BRUCELLA Y SUBUNIDAD b DE TOXINAS AB5 - Google Patents

QUIMERAS DE LUMAZINA SINTASA DE BRUCELLA Y SUBUNIDAD b DE TOXINAS AB5

Info

Publication number
AR096444A1
AR096444A1 ARP140102095A ARP140102095A AR096444A1 AR 096444 A1 AR096444 A1 AR 096444A1 AR P140102095 A ARP140102095 A AR P140102095A AR P140102095 A ARP140102095 A AR P140102095A AR 096444 A1 AR096444 A1 AR 096444A1
Authority
AR
Argentina
Prior art keywords
chimeric polypeptides
polynucleotides
shiga toxin
refers
chimeric
Prior art date
Application number
ARP140102095A
Other languages
English (en)
Inventor
Pilar Mejias Maria
Alberto Goldbaum Fernando
Zylberman Vanesa
Oliver Craig Patricio
Ghersi Giselle
Sandra Palermo Marina
Veronica Bentancor Leticia
Original Assignee
Inmunova S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmunova S A filed Critical Inmunova S A
Publication of AR096444A1 publication Critical patent/AR096444A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01078—6,7-Dimethyl-8-ribityllumazine synthase (2.5.1.78)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a polipéptidos quiméricos útiles como inmunógenos para inducir respuestas inmunes protectoras y anticuerpos neutralizantes contra la toxina Shiga (Stx) en mamíferos. Más específicamente, se refiere a polipéptidos quiméricos que comprenden un monómero de la subunidad B homopentamérica de la toxina Shiga 2, fusionada con el extremo N-terminal de un monómero de Iumazina sintasa de Brucella, y a complejos proteicos oligoméricos formados a partir de dichos polipéptidos quiméricos. Se refiere además a polinucleótidos y vectores que codifican dichos polipéptidos quiméricos, a células transgénicas que comprenden dichos polinucleótidos y vectores, y a composiciones farmacéuticas, tales como una vacuna, que comprenden dichos polipéptidos quiméricos y polinucleótidos quiméricos. También dentro del alcance de la presente están los anticuerpos que se unen a los polipéptidos quiméricos, un método para obtener anticuerpos que se unen específicamente a la subunidad B de la toxina Shiga 2 y métodos para reducir Ia carga bacteriana de Escherichia coli enterohemorrágica en mamíferos, que pueden ser utilizados para la prevención de, inter alia, el síndrome urémico-hemolítico (SUH).
ARP140102095A 2013-05-27 2014-05-27 QUIMERAS DE LUMAZINA SINTASA DE BRUCELLA Y SUBUNIDAD b DE TOXINAS AB5 AR096444A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361827713P 2013-05-27 2013-05-27

Publications (1)

Publication Number Publication Date
AR096444A1 true AR096444A1 (es) 2015-12-30

Family

ID=51136520

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140102096A AR096445A1 (es) 2013-05-27 2014-05-27 Anticuerpos que se unen específicamente a la subunidad b de la toxina shiga
ARP140102095A AR096444A1 (es) 2013-05-27 2014-05-27 QUIMERAS DE LUMAZINA SINTASA DE BRUCELLA Y SUBUNIDAD b DE TOXINAS AB5

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140102096A AR096445A1 (es) 2013-05-27 2014-05-27 Anticuerpos que se unen específicamente a la subunidad b de la toxina shiga

Country Status (10)

Country Link
US (1) US10633639B2 (es)
EP (1) EP3003348B1 (es)
JP (1) JP6674603B2 (es)
CN (1) CN105555293B (es)
AR (2) AR096445A1 (es)
BR (1) BR112015029776B1 (es)
CA (1) CA2913702C (es)
ES (1) ES2749120T3 (es)
MX (1) MX368441B (es)
WO (2) WO2014191903A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003348B1 (en) 2013-05-27 2019-07-10 Inmunova S.A. Chimeras of brucella lumazine synthase and beta subunit of ab5 toxins
KR20180132742A (ko) * 2016-04-11 2018-12-12 바이오제네시스 바고 우루과이 에스.에이. 바이러스 질환을 위한 범용 백신
CN111108126B (zh) * 2017-07-19 2024-04-26 非营利性组织佛兰芒综合大学生物技术研究所 血清白蛋白结合剂
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846435B1 (en) * 1998-05-20 2010-12-07 Teijin Limited Humanized antibodies that recognize Verotoxin II and cell line producing same
AR044603A1 (es) 2004-06-03 2005-09-21 Consejo Nac Invest Cient Tec Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
CN102532324B (zh) * 2010-12-30 2014-02-19 青岛红桥明勤生物科技有限公司 布氏杆菌基因工程亚单位疫苗的制备及其应用
EP3003348B1 (en) 2013-05-27 2019-07-10 Inmunova S.A. Chimeras of brucella lumazine synthase and beta subunit of ab5 toxins

Also Published As

Publication number Publication date
BR112015029776B1 (pt) 2023-02-07
WO2014191904A1 (en) 2014-12-04
CN105555293B (zh) 2021-08-03
EP3003348A1 (en) 2016-04-13
JP2016522209A (ja) 2016-07-28
AR096445A1 (es) 2015-12-30
NZ714547A (en) 2021-11-26
WO2014191903A1 (en) 2014-12-04
CN105555293A (zh) 2016-05-04
MX2015016347A (es) 2016-07-20
CA2913702C (en) 2023-08-01
EP3003348B1 (en) 2019-07-10
ES2749120T3 (es) 2020-03-19
JP6674603B2 (ja) 2020-04-01
US20160115459A1 (en) 2016-04-28
US10633639B2 (en) 2020-04-28
CA2913702A1 (en) 2014-12-04
BR112015029776A2 (pt) 2017-09-26
MX368441B (es) 2019-10-02

Similar Documents

Publication Publication Date Title
IL273035A (en) Polypeptides containing a subunit of SHIGA-free vaccine-free effector for mammalian applications
PH12019501360A1 (en) Glp-1 receptor agonists and uses thereof
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
NI201800062A (es) Enlazadores de ctla4
AR106908A1 (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación
MX365391B (es) Regimenes novedosos de cebadura-refuerzo que implican polipeptidos inmunogenicos codificados por polinucleotidos.
NZ761188A (en) Antibody molecules to tim-3 and uses thereof
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
MX371187B (es) Péptidos terapéuticos.
NZ750707A (en) Cot modulators and methods of use thereof
PH12014502438A1 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
AR096444A1 (es) QUIMERAS DE LUMAZINA SINTASA DE BRUCELLA Y SUBUNIDAD b DE TOXINAS AB5
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
WO2014136064A3 (en) Immunogenic fusion polypeptides
MX2014015977A (es) Vacuna de adn para usarse en pacientes con cancer pancreatico.
MX2016007939A (es) Nueva vacuna de adn dirigida contra msln para la inmunoterapia de cancer.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
TR201903886T4 (tr) Bağışıklık düzenleyici etkiye sahip olan propıonıbacterıum granulosumun paryetal fraksiyonu.
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
MX2017008406A (es) Conjugados de aminoacidos y peptidos y sus usos.
PH12015500890A1 (en) Vaccine for preventing porcine edema disease
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.
WO2014145923A3 (en) Synthetic immunogens for prophylaxis or treatment of tuberculosis
GB201120634D0 (en) Adjuvant polypeptide

Legal Events

Date Code Title Description
FG Grant, registration